We Are Passionate about women’s Health and Wellness
We Are Passionate
about women’s health and wellness
Viveve Medical is a medical technology company focused on women’s intimate health. Our mission is to enhance women’s lives by providing clinically proven, non-invasive, high quality products that improve their quality of life.
The Viveve® System is a dual-energy platform device. It incorporates Cryogen-cooled Monopolar Radiofrequency technology (CMRF) to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. Viveve’s endovaginal procedure is performed in 30-45 minutes and requires no anesthesia to maintain patient comfort.
What Sets Us Apart?
INTERNATIONALLY PATENTED TECHNOLOGY
Viveve has a strong, protected intellectual property portfolio of U.S. and International patents for its Cryogen-cooled Monopolar Radiofrequency (CMRF) dual energy technology platform and its use in vaginal tissue. Recently, a new U.S. Method Patent for Stress Urinary Incontinence was issued to further strengthen the Company’s IP portfolio.
ENTHUSIASTIC ACCEPTANCE WORLDWIDE
The Viveve System is currently used by physicians and women’s healthcare practitioners in over 50 countries worldwide. In the United States the Viveve System is approved for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances include its use for vaginal laxity and/or improvement of sexual function and/or improvement of stress urinary incontinence in women.
ROBUST CLINICAL SCIENCE
Scientific rigor in conducting clinical trials to prove safety and efficacy of our technology is foundational to Viveve. Large, multicenter, randomized, and blinded clinical trials conducted following U.S. and International regulatory agency requirements is Viveve’s tradition. Sound clinical studies provide evidence that demonstrates the effectiveness of a medical device to safely treat a specific medical condition. Viveve is continuing its commitment to robust science with initiation of its U.S. pivotal PURSUIT trial for improvement of stress urinary incontinence in women. Stress urinary incontinence is a condition that effects an estimated 25 – 30 million women worldwide.
ROBUST CLINICAL SCIENCE
Scientific rigor in conducting clinical trials to prove safety and efficacy of our technology is foundational to Viveve. Large, multicenter, randomized, and blinded clinical trials conducted following U.S. and International regulatory agency requirements is Viveve’s tradition. Sound clinical studies provide evidence that demonstrates the effectiveness of a medical device to safely treat a specific medical condition. Viveve is continuing its commitment to robust science with initiation of its U.S. pivotal PURSUIT trial for improvement of stress urinary incontinence in women. Stress urinary incontinence is a condition that effects an estimated 25 – 30 million women worldwide.
INTERNATIONALLY
PATENTED
TECHNOLOGY
Viveve has a strong, protected intellectual property portfolio of U.S. and International patents for its Cryogen-cooled Monopolar Radiofrequency (CMRF) dual energy technology platform and its use in vaginal tissue. Recently, a new U.S. Method Patent for Stress Urinary Incontinence was issued to further strengthen the Company’s IP portfolio.
ENTHUSIASTIC ACCEPTANCE WORLDWIDE
The Viveve System is currently used by physicians and women’s healthcare practitioners in over 50 countries worldwide. In the United States, the Viveve System is approved for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances include its use for vaginal laxity and/or improvement of sexual function and/or improvement of stress urinary incontinence in women.
Leadership
Leadership









Board of Directors






Medical Advisors
Need Help?
Contact Us
Customer Service
1-800-874-1398
Viveve
Where is
viveve?
Headquarters
345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 Driving Directions »
Telephone
(720) 696-8100
Fax
(720) 696-8199